The end really is nigh for Genasense in melanoma

Genta has finally put an end to the long and troubled development of its investigational antisense therapy Genasense for melanoma. While Harold Camping is just the latest in a series of false prophets predicting the end of the world, Genasense observers who had predicted the demise of the compound since before its first phase III melanoma failure back in 2004 have now been proved right.

Overall survival data from its Phase III AGENDA study reported today show no benefit with the product over dacarbazine chemotherapy alone in patients with advanced melanoma who had no prior chemotherapy